Genenta Science S.P.A. GNTA
We take great care to ensure that the data presented and summarized in this overview for Genenta Science S.p.A. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GNTA
View all-
Al Ti Global, Inc. New York, NY200KShares$881,2670.02% of portfolio
-
Algebris (Uk) LTD London, X045KShares$198,0000.05% of portfolio
-
Ubs Group Ag893Shares$3,9290.0% of portfolio
-
Morgan Stanley New York, NY500Shares$2,2000.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in GNTA
Top Purchases
Top Sells
About GNTA
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Insider Transactions at GNTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|